Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

522.83
-9.7000-1.82%
Post-market: 510.00-12.8300-2.45%18:33 EDT
Volume:338.24K
Turnover:178.08M
Market Cap:22.91B
PE:18.77
High:535.33
Open:534.11
Low:520.97
Close:532.53
52wk High:549.50
52wk Low:266.98
Shares:43.83M
Float Shares:41.99M
Volume Ratio:0.54
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.86
EPS(LYR):27.86
ROE:19.71%
ROA:12.42%
PB:3.23
PE(LYR):18.77

Loading ...

United Therapeutics Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Feb 27

RBC Raises Price Target on United Therapeutics to $643 From $587, Keeps Outperform Rating

MT Newswires Live
·
Feb 26

U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite

Reuters
·
Feb 26

United Therapeutics Corp : Jefferies Raises Target Price to $640 From $575

THOMSON REUTERS
·
Feb 26

United Therapeutics price target raised to $466 from $423 at Wells Fargo

TIPRANKS
·
Feb 26

Balancing Franchise Headwinds and Pipeline Upside: Rationale Behind a Hold on United Therapeutics

TIPRANKS
·
Feb 26

United Therapeutics Director Christopher Causey Disposes of Common Shares

Reuters
·
Feb 26

United Therapeutics price target raised to $569 from $546 at BofA

TIPRANKS
·
Feb 26

RBC says United Therapeutics TreSMI presents ‘material risk’ to MannKind

TIPRANKS
·
Feb 26

United Therapeutics Gains on Development of New Inhaler, 4Q Net Income Beat

Dow Jones
·
Feb 26

Leerink sees MannKind selloff as ‘overreaction’ to headline news

TIPRANKS
·
Feb 26

Liquidia reaction on United Therapeutics’ TreSMI reveal ‘overdone,’ says Needham

TIPRANKS
·
Feb 26

H.C. Wainwright sees MannKind selloff ‘potentially resetting’ value proposition

TIPRANKS
·
Feb 26

Balanced Hold on United Therapeutics Amid Near-Term Pressure and Key Late-Stage Pipeline Readouts

TIPRANKS
·
Feb 26

United Therapeutics announces ‘category killer product’ Tresmi

TIPRANKS
·
Feb 26

MannKind sinks after United Therapeutics announces soft-mist inhaler

TIPRANKS
·
Feb 26

Stock Track | United Therapeutics Soars 5.19% Intraday on Strong Q4 Earnings Beat and Tyvaso Growth

Stock Track
·
Feb 25

United Therapeutics Q4 revenue growth falls short of analyst expectations

Reuters
·
Feb 25

United Therapeutics reports Q4 EPS $7.70, consensus $7.24

TIPRANKS
·
Feb 25

Earnings Flash (UTHR) United Therapeutics Posts Q4 EPS $7.70, vs. FactSet Est of $6.67

MT Newswires Live
·
Feb 25